作者机构：
[郭志华] Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China;Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China;[尹紫薇; 郑惠珍] Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China<&wdkj&>Graduate School, Hunan University of Chinese Medicine, Changsha, Hunan 410208, China
通讯机构：
[Guo Zhihua] D;Department of Cardiology, The First Hospital of Hunan University of Chinese Medicine, Changsha, Hunan 410007, China
摘要：
Objective To evaluate the efficacy and safety of Qili Qiangxin Capsule(QLQXC)combined with western medicine in patients with ischemic cardiomyopathy(ICM)comorbid with heart failure(HF)for clinical application.Methods We searched relevant references in Chinese databases ...MORE Objective To evaluate the efficacy and safety of Qili Qiangxin Capsule(QLQXC)combined with western medicine in patients with ischemic cardiomyopathy(ICM)comorbid with heart failure(HF)for clinical application.Methods We searched relevant references in Chinese databases including China National Knowledge Infrastructure(CNKI),China Scientific Journal Database(VIP),Wanfang Database,and China Biology Medicine(CBM),as well as English databases including PubMed and Embase,from the foundation of the database to January 8,2023,without language restrictions.All statistical analyses,including subgroup and sensitivity analyses,were performed using the Review Manager(version 5.4)and Stata(version 15.0).Results QLQXC combined with western medicine significantly increased the endpoints of overall response rate(ORR)(P<0.00001),left ventricular ejection fraction(LVEF)(P<0.00001),the score of Minnesota Living with Heart Failure Questionnaire(MLHFQ)(P=0.0002),and 6-minute walking distance(6MWD)(P<0.00001),decreased left ventricular end-diastolic diameter(LVEDD)(P<0.00001),left ventricular end-systolic diameter(LVESD)(P=0.03),and pro-brain natriuretic peptide(pro-BNP)(P<0.00001),and reduced the incidence of rehospitalization(P=0.0003)and adverse events(AEs)(P=0.0006)compared with those under the conventional western therapy alone.Nonetheless,no significant difference was observed in reducing the mortality between the QLQXC combined with western medicine group and the western medicine group(P=0.30).Conclusion The combination therapy of QLQXC with western medicine can potentiate cardiac function and raise the quality of life in patients with ICM comorbid with HF.FEWER
摘要：
Objective:To investigate the mechanism of Jianpi Xiaoai Formula(健脾消癌方) in intervening in the activation and glycolysis of cancer-associated fibroblasts(CAFs) regulated by small molecule microRNA-21(miR-21) in exosomes derived from HCT116 colon cancer cells.Methods:Exoso...MORE Objective:To investigate the mechanism of Jianpi Xiaoai Formula(健脾消癌方) in intervening in the activation and glycolysis of cancer-associated fibroblasts(CAFs) regulated by small molecule microRNA-21(miR-21) in exosomes derived from HCT116 colon cancer cells.Methods:Exosomes secreted by HCT116 cells were collected using ultracentrifugation.Transmission electron microscopy was used to identify the morphology of HCT116-derived exosomes.Nanoparticle tracking analysis was performed to determine the size distribution of the exosomes.Western blot was conducted to detect the expression of exosomal marker proteins TSG101,Alix,and calnexin.Drug-containing serum was prepared with Jianpi Xiaoai Formula without exosomes,and HCT116 cells were treated with the drug-containing serum.The expression of miR-21 was measured by RT-PCR.Exosomes derived from HCT116 cells after treatment with exosome-free fetal bovine serum,exosome-free mouse serum,drug-containing exosome-free mouse serum,and transfection with miR-21 inhibitor(HCT116 exosomes 1.0 μg/mL group,blank mouse serum-treated HCT116 exosomes 1.0 μg/mL group,drug-containing mouse serum-treated HCT116 exosomes 1.0 μg/mL group,and miR-21 knockdown HCT116 exosomes 1.0 μg/mL group) were collected and used to intervene in human embryonic lung fibroblasts(HFL-1).Western blot and RT-PCR were performed to detect the protein and mRNA expression of alpha-smooth muscle actin(α-SMA),platelet-derived growth factor receptor-A(PDGFRA),and pyruvate kinase M2(PKM2).Results:Transmission electron microscopy revealed cup-shaped structures of exosome-like vesicles extracted from the supernatant of HCT116 cells.Particle size analysis showed that their diameter was mainly distributed between 80 nm and 200 nm.Western blot detected the expression of the exosomal marker proteins TSG101 and Alix in the exosomes.PKH67-labeled exosomes could be taken up by HFL-1 cells.Jianpi Xiaoai Formula reduced the expression of miR-21 derived from HCT116 cells in a time-and concentration-dependent manner.Compared with the blank control group,the HCT116 exosomes 1.0 μg/mL group and the blank mouse serum-treated HCT116 exosomes 1.0 μg/mL group showed upregulated relative protein and mRNA expression of α-SMA,PDGFRA,and PKM2(P<0.05 or P<0.01).Compared with the blank mouse serum-treated HCT116 exosomes 1.0 μg/mL group,the drug-containing mouse serum-treated HCT116 exosomes 1.0 μg/mL group and the miR-21 knockdown HCT116 exosomes 1.0 μg/mL group showed downregulated relative protein and mRNA expression of α-SMA,PDGFRA,and PKM2(P<0.05 or P<0.01).Conclusion:MiR-21 in exosomes derived from HCT116 cells can induce the activation of HFL-1 cells into CAFs.Jianpi Xiaoai Formula can regulate the expression of α-SMA and PDGFRA,inhibit the activation of CAFs,modulate the expression level of the glycolysis rate-limiting enzyme PKM2,and suppress colon cancer lung metastasis.FEWER
作者：
Huang, Yalan;Zhang, Yanling;Wu, Yongjun;Xiang, Qin;Yu, Rong
期刊：
Drug Design, Development and Therapy,2023年17:237-260 ISSN：1177-8881
通讯作者：
Yu, R.;Xiang, Q.
作者机构：
[Huang, Yalan; Yu, Rong] Hunan Univ Tradit Chinese Med, Grad Sch, Changsha 410208, Peoples R China.;[Huang, Yalan] Hunan Univ Tradit Chinese Med, Affiliated Hosp 1, Changsha 410021, Peoples R China.;[Zhang, Yanling] Hunan Univ Tradit Chinese Med, Coll Tradit Chinese Med, Changsha 410208, Peoples R China.;[Zhang, Yanling] Ningxia Med Univ, Gen Hosp, Ningxia 750003, Peoples R China.;[Wu, Yongjun] Hunan Univ Tradit Chinese Med, Coll Pharm, Changsha 410208, Peoples R China.
通讯机构：
[Qin Xiang] S;[Rong Yu] G;Science and Technology Department, Hunan University of Traditional Chinese Medicine, Changsha, 410208, People’s Republic of China<&wdkj&>Graduate School, Hunan University of Traditional Chinese Medicine, Changsha, 410208, People’s Republic of China
关键词：
apoptosis;diabetic cardiomyopathy;network pharmacology;pharmacochemistry;PI3K/Akt pathway;Zuogui Jiangtang Shuxin formula
摘要：
BACKGROUND: Many epidemiological studies have shown that idiopathic pulmonary fibrosis (IPF) is a risk factor for lung cancer (LC), but these studies do not provide direct evidence of a causal association between the two diseases. We investigated the causal association between IPF and different pathological types of LC based on the Mendelian randomization (MR) study. METHODS: The genome-wide association study (GWAS) data of IPF and LC were obtained from the latest published articles, and instrumental variables (IVs) for analysis were obtained after screening and eliminating the confounders. MR Analysis was carried out with the help of random effects inverse variance weighting (re-IVW), MR-egger, and weighted median method, and a comprehensive sensitivity test was conducted. RESULTS: The results of re-IVW analysis showed that IPF may increase the risk of lung squamous cell carcinoma (LUSC) (OR = 1.045, 95% CI 1.011 to 1.080, P = 0.008). In addition, no causal relationship was found between IPF and overall LC (OR = 0.977, 95% CI 0.933 to 1.023, P = 0.32), lung adenocarcinoma (LUAD) (OR = 0.967, 95% CI 0.903 to 1.036, P = 0.345) and small cell lung carcinoma (SCLC) (OR = 1.081, 95% CI 0.992 to 1.177, P = 0.074). A comprehensive sensitivity analysis ensured the reliability of the study. CONCLUSION: In conclusion, from the perspective of genetic association, we found that IPF is an independent risk factor for LUSC and may increase the risk of LUSC, but no such causal relationship was found in LUAD and SCLC.
作者：
Tan, Yan;Nie, Duo Rui;Cao, Yang;Ke, Chao;Pan, Jiang;...
期刊：
Neurological Sciences,2023年 ISSN：1590-1874
通讯作者：
Zhang, W
作者机构：
[Tan, Yan; Zhang, Wei; Ke, Chao; Cao, Yang; Pan, Jiang; Shi, Wen Ying] Hunan Univ Chinese Med, Dept Acupuncture Moxibust & Tuina, Affiliated Hosp 1, Changsha, Peoples R China.;[Nie, Duo Rui] Hunan Univ Chinese Med, Grad Sch, Changsha, Peoples R China.
通讯机构：
[Zhang, W ] H;Hunan Univ Chinese Med, Dept Acupuncture Moxibust & Tuina, Affiliated Hosp 1, Changsha, Peoples R China.
关键词：
Alzheimer’s Disease;Bibliometrics;Omics;Trends;Web of Science
摘要：
BACKGROUND: Alzheimer's disease (AD) is a progressive neurodegenerative disease with an insidious onset. The widespread application of omics techniques in AD has attracted considerable attention. We aimed to make a comprehensive analysis of published omics articles on AD in order to determine the research profile and application trends of omics techniques in AD. METHODS: This study utilizes bibliometric and visual methods including a map collaboration map, co-citations, and keywords to identify knowledge structures, hot topics, and research trends based on 6,828 publications from the Web of Science Core Collection (WoSCC) database. RESULTS: The results of this study showed that 5654 institutions from 91 countries published articles in this field. The USA, China, and the UK played a leading role in publishing numerous articles in relevant journals as well as prolific institutions and authors, respectively. This paper collects a large number of literatures on the application of AD omics technology from the WoSCC database and found the omics technology applied to AD is mainly based on genomics technology. The application of transcriptomics technology has shown an increasing trend in recent years, and the application of multi-omics technology will be the general trend in the future. CONCLUSION: The development status, frontier hotspots, and general trends of omics application technologies are reviewed. This article will provide intelligence support to researchers and institutions in the field of Alzheimer's omics research and applications from a practical perspective.
